The phase 3 ADVOCATE trial assessed avacopan for the treatment of ANCA-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]). Concerns about the original 2019 primary endpoint adjudication prompted a blinded, independent re-adjudication of all participants' primary outcomes in 2026. The 2026 re-analysis was intended to reassess remission and sustained remission outcomes using procedures aligned with the original adjudication charter.
Participants with GPA or MPA were randomized 1:1 to receive oral avacopan 30 mg twice daily or an oral prednisone taper, each administered alongside rituximab- or cyclophosphamide-based standard of care. The analyses reported are for the intent-to-treat population (n = 330).
In 2026, the Duke Clinical Research Institute Clinical Events Classification group conducted an independent, blinded committee readjudication. The committee re-evaluated Birmingham Vasculitis Activity Score (BVAS), relapse, and remission status for each participant during weeks 26 through 52, following procedures consistent with the original adjudication charter. The pre-specified primary endpoints were remission at week 26 and sustained remission at week 52.
Per the original analysis plan, noninferiority and superiority were assessed by the difference in primary outcome rates (avacopan minus prednisone taper). Noninferiority was declared if the lower bound of the 95% confidence interval (CI) exceeded −20.0 percentage points; superiority required the lower bound to exceed 0.0 percentage points. Adjusted differences and 95% CIs are reported for the readjudicated endpoints.
In the 2026 readjudication, remission at week 26 occurred in 68.1% (113/166) of participants randomized to avacopan and 67.1% (110/164) of those randomized to a prednisone taper. The adjusted difference was 2.2% (95% CI, −7.5 to 11.9). For comparison, the 2019 primary adjudication reported remission rates of 72.3% (120/166) with avacopan and 70.1% (115/164) with prednisone (adjusted difference 3.4%; 95% CI, −6.0 to 12.8).
These 2026 results meet the prespecified noninferiority threshold, as the lower bound of the 95% CI (−7.5) is greater than the −20.0 percentage-point margin.
Sustained remission at week 52 in the 2026 readjudication was achieved by 61.4% (102/166) of participants receiving avacopan and 52.4% (86/164) receiving the prednisone taper. The adjusted difference was 9.8% (95% CI, −0.3 to 19.9). In the 2019 adjudication, sustained remission rates were 65.7% (109/166) versus 54.9% (90/164) for avacopan and prednisone, respectively (adjusted difference 12.5%; 95% CI, 2.6 to 22.3).
Although the 2026 readjudication shows a consistent numerical advantage favoring avacopan at week 52, the lower bound of the 95% CI (−0.3) did not exceed 0.0, so statistical superiority was not demonstrated in this re-analysis.
Concordance between the original 2019 adjudication and the 2026 independent readjudication was high: 95.2% agreement for remission at week 26 and 93.6% agreement for sustained remission at week 52. These figures reflect substantial consistency across adjudication efforts.
The 2026 blinded readjudication supports the primary conclusion that avacopan is noninferior to a prednisone taper for inducing remission at week 26 and for sustained remission at week 52 in patients with GPA or MPA, based on prespecified noninferiority margins. The report additionally notes a median 81% reduction in glucocorticoid exposure observed in the avacopan group compared with the prednisone taper group. While both the 2019 and 2026 adjudications show a consistent numerical benefit for avacopan at week 52, the 2026 re-analysis did not meet the predefined criterion for statistical superiority.
The report lists competing interests for multiple authors, including consulting fees, research support, stock holdings, and employment; several authors are employees of Amgen, Inc. The authors confirm that ethical approvals from a large number of institutional review boards were obtained for the original phase 3 trial. The clinical trial registration is provided (NCT02994927). The underlying data are not publicly available; qualified researchers may request access subject to an internal review and data-sharing agreements under applicable governance and privacy protections.